Support for People and Communities Affected by the 2026 Kumamoto Prefecture Earthquake

We express our deepest condolences to the people who lost their lives and to their families, and our sincere sympathies to those affected by the Kumamoto Prefecture Earthquake.

Hyogo, Japan – August 6, 2026 – JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”). announced today that it has decided to donate ¥5 million to Kumamoto Prefecture to support the relief efforts for those affected by this earthquake and to support the recovery and reconstruction of the disaster-stricken areas.

We pray for the swift reconstruction of the affected region.

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world’s most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients’ lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia.
Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including partners, patients and employees. We strive to expand the possibilities
for patients while accelerating medical advancement at a global level. For more information,
please visit JCR’s global website: https://jcrpharm.com/.